Absorption and Metabolism of cis-9,trans-11-CLA and of Its Oxidation Product 9,11-Furan Fatty Acid by Caco-2 Cells

Thorsten Buhrke · Roswitha Merkel · Imme Lengler · Alfonso Lampen

Introduction

Conjugated linoleic acids (CLA) are polyunsaturated fatty acids that are present in many natural food sources. The term CLA describes a group of positional and geometric isomers of linoleic acid (LNA) derivatives having conjugated double bounds. The conversion from LNA to CLA occurs in the rumen of ruminants by bacterial metabolic activity [1]. Therefore, the main source for CLA taken up by humans is foodstuff derived from ruminants such as milk or meat.

Over the last decade the interest in CLA has arisen because various publications suggested that CLA may have many different positive physiological effects. In vitro, CLA inhibited the growth of various human cancer cells such as colon [2], mammary [3] and prostate [4] cancer cell lines. This anticarcinogenic effect was also determined in vivo where supplementation with CLA resulted in a decreased size of chemically or genetically induced tumors in experimental animals (reviewed in [5]). In addition, CLA seem to prevent atherosclerosis [6, 7, 8] and may improve the immune system [9, 10]. On the other hand, some publications describe negative effects of CLA supplementation, i.e. the induction of non-alcoholic hepatic steatosis in mice [11], the decrease of insulin sensitivity in human subgroups [12], or the increase in proinflammatory cytokines in human adipocytes in vitro [13]. In the past decade,
Attention has predominantly been drawn on a potential anti-adipogenic role of CLA as these substances are proposed to have a positive effect on body composition by decreasing body fat mass and increasing lean muscle mass (reviewed in [14]). In the case of body composition, the CLA isomer trans-10, cis-12-CLA (t10,c12-CLA) seems to be responsible for reduction of body fat [15]. On the other hand, it was proposed that the isomer cis-9,trans-11-CLA (c9,t11-CLA) was more effective concerning the inhibition of tumor development [16]. Milk and meat of ruminant animals contain 28 different CLA isomers, and the most abundant isomer in food is the c9,t11-CLA isomer, which represents up to 80% of total CLA.

Due to the reported positive effects of CLA on body mass composition and despite controversial data and some observed negative effects of CLA, these compounds are already available in numerous formulas of food supplements and are currently being discussed for their use as food additives. CLA are classified as “novel foods” in Europe and a premarketing risk assessment of CLA is a mandatory part of the novel food approval. For a reliable risk assessment of CLA it is necessary to focus additionally on the oxidation products of CLA, the furan fatty acids (furan-FA).

Furan-FA are comprised of a furan ring flanked by one alkyl and one carboxyl side chain in the \( \alpha \)-positions of the furan ring. It has been shown that in the presence of air CLA can react with dioxygen to form furan-FA [17] (Fig. 1). Therefore, if CLA-containing food supplements are consumed, significant amounts of furan-FA may be taken up by the consumer in parallel. Up to now, hardly anything is known about the toxicological potential of furan-FA. The presence of the aromatic furan ring system in furan-FA gives rise to the assumption that these compounds may have hazard potential since furan itself and numerous furan derivatives have shown themselves to have properties of toxicological relevance (reviewed in [18]).

The aim of our study was to investigate the absorption and the metabolism of furan-FA by human intestinal cells. The well-established Caco-2 system was employed for this study as it is a widely used in vitro model for the intestinal barrier. Differentiated Caco-2 cells are known to form a tight cellular monolayer with morphological and biochemical properties very similar to those of enterocytes of the small intestine [19, 20]. In addition, the Caco-2 system is a well-established model for intestinal lipid metabolism [21].

**Experimental Materials and Methods**

**Chemicals and Fatty Acids**

All chemicals were purchased from Merck (Darmstadt, Germany) or Sigma-Aldrich (Taufkirchen, Germany) in the highest available purity. The CLA isomers cis-9,trans-11-octadecadienoic acid (c9,t11-CLA) and the furan fatty acid 9,12-epoxy-9,11-octadecadienoic acid (9,11-furan-FA) were obtained from Biotrend (Köln, Germany). LNA was purchased from Sigma-Aldrich (Taufkirchen, Germany). All fatty acids were dissolved in DMSO to get 0.1 M stock solutions.

**Cell Culture and Treatment with Fatty Acids**

Cells were obtained from the European Collection of Cell Culture (ECACC). Culture media and supplements were obtained from PAA Laboratories GmbH (Pasching, Austria). The human adenocarcinoma cell line Caco-2 (ECACC No. 860 10 202) was cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified atmosphere of 5% CO\(_2\) at 37 °C. Cells were passaged every 3–4 days by treatment with 0.1% trypsin and 0.04% EDTA and then plated at a density of 1.3–2 × 10\(^4\) cells/cm\(^2\).

For experimentally treatment with fatty acids, cells were allowed to attach by cultivating overnight in medium containing 10% FCS and were then incubated in serum-free medium supplemented with 1% insulin–transferrin–selenium...
Caco-2 cells in 100 l
Cells were plated in 96-well plates with 7,500 cells/well for Cell Viability Assay (Zeiss, Jena, Germany). Observer microscope equipped with a digital camera. The microscopy studies were performed with a Axio Taufkirchen, Germany) was performed. Cells were washed with Phosphate Buffered Saline (PBS) and fixed with 3.7% formaldehyde for 1 h. 0.3% Oil-Red-O in isopropanol was then added directly to the fixed cells and incubated for 1 h. The microscopy studies were performed with a Axio Observer microscope equipped with a digital camera (Zeiss, Jena, Germany).

Cell Viability Assay

Cells were plated in 96-well plates with 7,500 cells/well for Caco-2 cells in 100 µl medium. After 2 days of treatment with fatty acids cell viability was estimated by the Cell-Titer-Blue® Cell Viability Assay (CTB Assay) (Promega, Madison, WI). Assays were performed by adding 20 µl of a 1:4 dilution of the CTB reagent in phosphate-buffered saline (PBS) directly to the cells cultured in 100 µl medium, incubating for 1 h at 37 °C and then measuring fluorescence at 540/590 nm with a Mithras Multimode Reader LB 940 (Berthold Technologies, Vienna, Austria). Values are expressed as percentages of the negative control which was exposed to medium containing 0.1% DMSO and which was taken as 100%. As a positive control for cytotoxicity: cells were exposed to medium containing 0.05% Triton X-100.

Extraction of Total Cellular Lipids and Fatty Acid Derivatization

Caco-2 cells were incubated with 100 µM of LNA, c9,t11-CLA or 9,11-furan-FA for 48 h. Cells were washed twice with PBS, and after treatment with trypsin/EDTA cells were transferred to reaction tubes. 20 µl of a 10 mM solution of butylated hydroxytoluene (BHT) in acetonitrile was applied to the cell suspensions to protect the lipids from oxidative damage. Subsequently, cells were lyophilized to completely remove the water and total lipids were extracted twice from the dried cell pellet with 0.7 ml of a 2:1 (v/v) chloroform:methanol mixture. 150 µl of a 20% solution of BF3 in methanol was applied to the lipid extracts, and transmethylation was conducted for 10 min at 70 °C. Methylated fatty acids were extracted with 1 ml of hexane, dried over anhydrous sodium sulfate, concentrated in vacuo and finally dissolved in 200 µl hexane.

GC/MS Analysis

GC/MS analysis was conducted with an Agilent 7890A gas chromatograph coupled to an Agilent MSD 5975C mass spectrometer. Methylated fatty acids were separated with an Rt-2560 column (100 m × 0.25 mm × 0.2 µm; Restek, Bad Homburg, Germany) by using helium as the carrier gas at a flow rate of 1 ml/min. 2 µl of each samples was applied to the cold injection system (splitless mode, 15 °C) by taking advantage of an MP5 autosampler (Gerstel, Müllheim, Germany). The oven program was as follows: 6 min at 35 °C, ramp to 165 °C at 65 °C/min, 2 min at 165 °C, 1 min at 180 °C, 0.5 min at 190 °C, 1 min at 210 °C. Methylated fatty acids were identified by comparison of retention times with authentic standards and by the fragmentation pattern in the mass spectra. The artificial methylated fatty acid C19:0 was used as the internal standard. Mass spectra were recorded both in the SCAN modus and in the SIM modus to increase sensitivity. The quantitation limit of the method was 0.25 ng/µl for each individual fatty acid.

Results

Viability of Caco-2 Cells

In this study we focused on c9,t11-CLA, the major CLA isomer in foodstuff, and on its oxidation product 9,11-furan-FA. Moreover, the metabolic precursor of c9,t11-CLA, LNA, was included in the study.

To analyse potential cytotoxic effects of LNA, c9,t11-CLA and 9,11-furan-FA, Caco-2 cells were incubated with various concentrations of these substances. Subsequently, cellular viability was tested by using the CTB assay. As shown in Fig. 2, incubation of the cells with up to 100 µM of the respective substance did not affect cellular viability whereas cellular viability was decreased to a level of about 3% upon incubation of the cells with medium containing 0.05% Triton X-100 which was used as positive control. Thus, none of the substances tested in this study displayed cytotoxic potential to Caco-2 cells up to a level of 100 µM.

Fatty Acid Absorption by Caco-2 Cells

Caco-2 cells have the capacity to absorb free fatty acids and to incorporate them into triglycerides for storage in lipid droplets [22]. To analyze whether the enzymatic machinery of Caco-2 accepts furan-FA as a fatty acid-type substrate at all, lipid droplet staining was conducted with LNA-, CLA- and furan-FA-treated cells in order to visualize cellular absorption of the respective fatty acid. Caco-2 cells were incubated either with LNA, c9,t11-CLA, or
9,11-furan-FA, and Oil-Red-O-staining of the cells was conducted after 48 h of incubation in order to visualize the formation of intracellular lipid droplets. In control cells, intracellular red stain was rarely visible, whereas numerous small lipid droplets were stained in cells that had been incubated with 10 μM LNA, c9,t11-CLA or 9,11-furan-FA (Fig. 3). Incubation of the cells with 100 μM of the respective free fatty acid yielded cells full of large lipid droplets (Fig. 3). Therefore, Fig. 3 clearly illustrates that lipid droplet formation in Caco-2 cells increased with increasing concentrations of free fatty acid offered to the cells, independent of the type of fatty acid. Moreover, microscopic inspection of numerous cells indicated that Caco-2 cells treated with 100 μM of the respective fatty acid tend to be enlarged in size due to lipid droplet formation. In these experiments there was no observation of specific alterations in cell morphology such as shrinking of the cells that might point to toxic effects induced by fatty acid treatment. Thus, in sum, Caco-2 cells seem to absorb 9,11-furan-FA and to store it as triglycerides in lipid droplets as they do with LNA and c9,t11-CLA.

### Analysis of Fatty Acid Composition

To follow the fate of the fatty acids taken up by the cells, a GC/MS method was employed to analyze cellular fatty acid composition in more detail. For this purpose, total cellular lipids were extracted from Caco-2 cells that had been incubated with 100 μM of LNA, c9,t11-CLA, or 9,11-furan-FA, respectively. After lipid hydrolysis and fatty acid derivatization, the resulting mixture of fatty acid methyl esters was separated by gas chromatography. Fatty acid identification was achieved by subsequent MS analysis of individual peaks. The relative amount of the respective fatty acid was calculated from the peak area in relation to the peak area of the internal standard. The results of this analysis are summarized in Table 1.

Incubation of the cells with LNA resulted in an approximately four-fold increase in the relative intracellular content of LNA and in a concomitant relative decrease of the amount of the other fatty acids with two exceptions. Compared to the control cells, the relative amount of the well-known LNA-metabolite 20:4n-6 increased upon incubation of the cells with LNA. In addition, a small amount of t9,t11-CLA was detectable in the samples obtained from LNA-incubated cells.

In the case of c9,t11-CLA, an approx. 20-fold increase in the relative intracellular amount of this substance was observed. In addition, the relative amount of the CLA isomers c9,c11-CLA and t9,t11-CLA increased whereas the relative content of the remaining fatty acids decreased.

Incubation of the cells with 9,11-furan-FA yielded an approx. 20-fold increase in the relative intracellular amount of this compound and a simultaneous decrease of the relative content of all other fatty acids. There was, however, an additional peak in the gas chromatogram that was neither present in the chromatogram of the control cells nor in the chromatograms of the cells incubated with LNA or c9,t11-CLA. The peak area of the additional peak was at a level of about 10% compared to the area of the 9,11-furan-FA peak (data not shown). Comparison of the mass spectra of 9,11-furan-FA and of the unknown substance from the
additional peak revealed that this substance must be a metabolite of 9,11-furan-FA (Fig. 4). Two major peaks with m/z 165 and m/z 179 in the mass spectrum of 9,11-furan-FA (Fig. 4a) can be explained by the cleavage of the compound between carbon atoms C7 and C8, and between C6 and C7, respectively. Additional β-cleavage of these products between C13 and C14 results in masses of m/z 95 and m/z 107, respectively, additional major peaks in spectrum of Fig. 4a. Since these four masses are also present in the mass spectrum of the unknown metabolite (Fig. 4b), it can be concluded that this metabolite is a derivative of 9,11-furan-FA. Moreover, preservation of these four masses indicates that the furan ring is still intact in the metabolite and that it was not altered upon cellular metabolic activity.

Since the molecule peak of 9,11-furan-FA with m/z 308 (Fig. 4a) was shifted to a mass of m/z 336 (Fig. 4b), the mass of the metabolite has increased by 28 atomic units (a.u.). In addition, the series of m/z 237, m/z 251, m/z 265 and m/z 277 of Fig. 4a has shifted by 28 a.u. to m/z 265, m/z 279, m/z 293 and m/z 305, respectively, in Fig. 4b. The increase of 28 a.u. can be explained by the addition of two methylene groups to 9,11-furan-FA, resulting in the C20-derivative as depicted in the insert of Fig. 4b.
**Discussion**

In the past decades, CLA have been intensively investigated in numerous in vivo and in vitro studies. These substances are supposed to have various positive effects on human health. Therefore, CLA are already available as food supplements, and the risks and benefits of supplementation of foodstuff with CLA are currently under discussion. Surprisingly, the putative presence of furan-FA in CLA preparations plays no role in these discussions so far, although it was shown that furan-FA might arise from auto-oxidation of CLA in the presence of molecular oxygen [17]. From a toxicological point of view, furan-FA are of particular interest because furan-FA harbor a furan ring system, and furan and furan derivatives have been shown to be toxic compounds (reviewed in [18, 23, 24]). In the liver, furan and furan derivatives are activated by CYP2E1 to form epoxides, and subsequently these epoxides are further converted to yield aldehydes in some cases [25–27]. Epoxides as well as aldehydes can directly react with lipids, proteins or DNA and are therefore toxic to cellular systems. Due to their reactivity to DNA, they are potent mutagens. Therefore, the toxicological characterization of furan-FA has to be conducted in parallel to the current risk and benefit assessment of CLA supplementation.

It is well-known that plants produce furan-FA as secondary metabolites. These furan-FA of plant origin carry methyl groups at one or both \( \beta \)-positions of the furan ring. If these compounds are ingested with food, the methyl groups are converted by liver metabolic activity to carboxylic acid
The furan-FA analyzed in this study, however, showed no cytotoxic effect up to a concentration of 100 μM.

The Caco-2 cell line used in this study serves as a model for human intestinal enterocytes. Caco-2 cells have been shown to be capable of lipid metabolism including triglyceride synthesis and lipid droplet formation. Moreover, these cells express numerous P450 enzymes and have the capacity to detoxify various compounds. Among others, the CYP2E1 enzyme has shown itself to be expressed by Caco-2 cells [31]. Therefore, the Caco-2 system was the ideal model to study uptake and metabolism of furan-FA by human intestinal cells, because triglyceride formation as well as β-oxidation and CYP-mediated activation of the furan ring could be examined by using this cell line. Our results indicate that furan-FA are taken up by the cells, esterified to triglycerides and stored in lipid droplets. At first glance, there seems to be no difference in the uptake and conversion of LNA, CLA and the corresponding furan-FA by Caco-2 cells. Hydrolysis of total cellular lipids and subsequent fatty acid quantification revealed that LNA and CLA were partly converted to related fatty acids by the cells (Table 1).

In the case of LNA, a relative increase in arachidonic acid (20:4n-6) was observed. It is well-known that mammalian cells have the capacity to use LNA as a precursor for the formation of 20:4n-6. Fatty acid elongation is facilitated by the activity of ELOVL5, a member of the ELOVL protein family [32, 33] followed by the subsequent insertion of two additional double bonds. Thus, based on our lipid analysis, there is some indication that Caco-2 cells do not only take up fatty acid and store them as triglycerides in lipid droplets, but the cells also seem to elongate fatty acids prior to triglyceride formation.

Incubation of the cells with c9,t11-CLA resulted in a relative increase in the CLA isomers c9,e11-CLA and t9,t11-CLA (Table 1). It has recently been shown that the human colon cell line HT-29 can convert t11,t13-CLA into its isomer c9,t11-CLA probably by an enzymatic two-step saturation/desaturation reaction [34]. This might explain the appearance of the c9,e11-CLA isomer in our experiment but can not explain the presence of the t9,t11-CLA isomer as mammalian cells do not introduce trans double bonds into fatty acids. We can not exclude that cis–trans isomerization might have occurred chemically during sample preparation or derivatization. By using a solution of c9,t11-CLA in control experiments, however, there was no indication of cis–trans isomerization under the given experimental conditions (data not shown). Finally, the unexpectedly high amounts of the different CLA isomers and of 9,11-furan-FA already in the control cells might have been due to the fact that the cells had been incubated in a medium containing 10% fetal calf serum (FCS) that may contain significant amounts of bovine-specific fatty acids.

Lipid extracts from cells incubated with 9,11-furan-FA yielded an additional peak in the gas chromatogram that was not detected with extracts from cells that had been treated with LNA or c9,t11-CLA. Based on the corresponding mass spectrum, we propose a structure for the furan-FA-derived metabolite as presented in Fig. 4b. From a biological point of view, the presence of this compound can simply be explained by the elongation of 9,11-furan-FA probably again by the action of a member of the ELOVL protein family and the subsequent reduction of the condensation product as described for LNA above.

Finally, GC/MS analysis of fatty acid extracts derived from furan-FA-treated Caco-2 cells gave no indication for any modification at the furan ring system. There were no metabolites detected that might have been formed upon epoxide formation or any other modification of the furan ring. Therefore, furan-FA might be either not accepted as a substrate for the cellular CYP machinery, or esterification of furan-FA to form triglycerides and subsequent storage in lipid droplets might be favoured in comparison to the postulated oxidative conversion of the furan ring. In conclusion, furan-FA taken up by human intestinal cells seem to end up preferentially in lipid metabolic pathways such as fatty acid elongation and triglyceride formation, whereas the furan ring present in furan-FA does not seem to be attacked by detoxifying enzymes. In vivo, intestinal cells pack triglycerides into chylomicrones which are VDL-like particles and secrete them into the blood stream. These chylomicrones are then taken up by liver cells where they are further metabolized. Since our results indicate that the furan ring system of furan-FA was not affected by the metabolic activity of intestinal cells, we will address the question in future studies as to whether the furan ring might be attacked by liver metabolic activity.

Acknowledgments We thank Dr. Lukrecia Benesch-Girke for giving helpful advice in the GC/MS measurements. Linda Brandenburger and Anja Köllner are acknowledged for their technical assistance. This project was funded by the Deutsche Forschungsgemeinschaft (DFG project LA 1177/5-4). There are no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
References

1. Kepler CR, Hirons KP, McNeill JJ, Tove SB (1966) Intermediates and products of the biodehydrogenation of linoleic acid by Butyrivibrio fibrisolvens. J Biol Chem 241:1350–1354
2. Lampen A, Leifheit M, Voss J, Nau H (2005) Molecular and cellular effects of cis-9,trans-11-conjugated linoleic acid in enterocytes: effects on proliferation, differentiation, and gene expression. Biochim Biophys Acta 1735:30–40
3. Chuo H, Yamasaki M, Nau S, Koyanagi N, Tachibana H, Yamada K (2003) Effect of conjugated linoleic acid isomers on growth factor-induced proliferation of human breast cancer cells. Cancer Lett 202:81–87
4. Kim EJ, Shin HK, Cho JS, Lee SK, Won MH, Kim JW, Park JH (2006) trans-10, cis-12 conjugated linoleic acid inhibits the G1-S cell cycle progression in DU145 human prostate carcinoma cells. J Med Food 9:293–299
5. Kelley NS, Hubbard NE, Erickson KL (2007) Conjugated linoleic acid isomers and cancer. J Nutr 137:2599–2607
6. Lee KN, Kritchevsky D, Pariza MW (1994) Conjugated linoleic acid and atherosclerosis in rabbits. Atherosclerosis 108:19–25
7. Nicolosi RJ, Rogers EJ, Kritchevsky D, Scimeca JA, Huth PJ (1997) Dietary conjugated linoleic acid reduces plasma lipoproteins and early aortic atherosclerosis in hypercholesterolemic hamsters. Artery 226:266–277
8. Kritchevsky D, Tepper SA, Wright S, Tso P, Czarnecki SK (2000) Influence of conjugated linoleic acid (CLA) on establishment and progression of atherosclerosis in rabbits. J Am Coll Nutr 19:472S–477S
9. Cook ME, Miller CC, Park Y, Pariza M (1993) Immune modulation by altered nutrient metabolism: nutritional control of immune-induced growth depression. Poult Sci 72:1301–1305
10. O’Shea M, Bassaganya-Riera J, Mohede IC (2004) Immunomodulatory properties of conjugated linoleic acid. Am J Clin Nutr 79:1199S–1206S
11. Clement L, Poirier H, Niot I, Bocher V, Guerre-Millo M, Krief S, Staels B, Besnard P, chaun CA, Huth PJ (2002) Dietary conjugated linoleic acid induces hyperinsulinemia and fatty liver in the mouse. J Lipid Res 43:1400–1409
12. Riserus U, Vessby B, Arnlöv J, Basu S (2004) Effects of cis-9,trans-11 conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men. Am J Clin Nutr 80:279–283
13. Chung S, Brown JM, Provo JN, Hopkins R, McIntosh MK (2005) Conjugated linoleic acid promotes human adipocyte insulin resistance through NFκB-dependent cytokine production. J Biol Chem 280:38445–38456
14. Baddini FA, Fernandes PA, da Ferreira CN, Goncalves RB (2000) Conjugated linoleic acid (CLA): effect modulation of body composition and lipid profile. Nutr Hosp 24:422–428
15. Park Y, Storkson JM, Albright KJ, Liu W, Pariza MW (1999) Evidence that the trans-10, cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids 34:235–241
16. Churrucu I, Fernandez-Quintela A, Portillo MP (2009) Conjugated linoleic acid isomers: differences in metabolism and biological effects. Biofactors 35:105–111
17. Yurawecz MP, Hood JK, Mossoba MM, Roach JA, Ku Y (1995) Furan fatty acids determined as oxidation products of conjugated octadecadienoic acid. Lipids 30:595–598
18. Heppner CW, Schlatter JR (2007) Data requirements for risk assessment of furan in food. Food Addit Contam 24(Suppl 1): 114–121
19. Artursson P, Palm K, Luthman K (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27–43
20. Pinto M, Robine-Leon S, Appay MD, Kedinger N, Triadou N, Dussaux E, Lacroix P, Simon-Assman K, Haffen K, Fogh J, Zwieba A (1983) Enterocyte like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell 47:323–330
21. Levy E, Mehran M, Seidman E (1995) Caco-2 cells as a model for intestinal lipoprotein synthesis and secretion. FASEB J 9:626–635
22. Trotter PJ, Ho SY, Storch J (1996) Fatty acid uptake by Caco-2 human intestinal cells. J Lipid Res 37:336–346
23. Stich HF, Rosin MP, Wu CH, Powrie WD (1981) Clastogenicity of furans found in food. Cancer Lett 13:89–95
24. Bakhya N, Appel KE (2010) Toxicity and carcinogenicity of furan in human diet. Arch Toxicol 84:563–578
25. Chen LJ, Hecht SS, Peterson LA (1995) Identification of cis-2-buten-1,4-dial as a microsomal metabolite of furan. Chem Res Toxicol 8:903–906
26. Kedderis GL, Carfagna MA, Held SD, Batra R, Murphy JE, Gargas ML (1993) Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro. Toxicol Appl Pharmacol 123:274–282
27. Parmar D, Burka LT (1993) Studies on the interaction of furan with hepatic cytochrome P-450. J Biochem Toxicol 8:1–9
28. Spillert G (2005) Furan fatty acids: occurrence, synthesis, and reactions. Are furan fatty acids responsible for the cardioprotective effects of a fish diet? Lipids 40:755–771
29. Prinsep MR, Blunt JW, Munro MH (1994) Isolation of the furan derivatives and a new fatty acid from a Taiwanese marine sponge Plakortis simplex. J Nat Prod 64:324–327
30. Shen YC, Prakash CV, Kuo YH (2001) Three new furan derivatives and a new fatty acid from a Taiwanese marine sponge Butyrivibrio fibrisolvens. J Nat Prod 64:324–327
31. Lampen A, Bader A, Bestmann T, Winkler M, Witte L, Borlak JT, Joshua TB (1998) Catalytic activities, protein- and mRNA-expression of cytochrome P450 isoenzymes in intestinal cell lines. Xenobiotica 28:429–441
32. Guillou H, Zadravec D, Martin PG, Jacobsson A (2010) The key roles of elongases and desaturases in mammalian fatty acid metabolism: insights from transgenic mice. Prog Lipid Res 49:186–199
33. Leonard AE, Bobik EG, Dorado J, Kroeger PE, Chuang LT, Thurmond JM, Parker-Barnes JM, Das T, Huang YS, Mukerji P, (2000) Cloning of a human cDNA encoding a novel enzyme involved in the elongation of long-chain polyunsaturated fatty acids. Biochem J 350(Pt 3):765–770
34. Degen C, Ecker J, Piegholdt S, Liebisch G, Jahreis G (2011) Metabolic and growth inhibitory effects of conjugated fatty acids in the cell line HT-29 with special regard to the conversion of t11, t13-CLA. Biochim Biophys Acta 1811:1070–1080